Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate
Samit K Bhattacharya, Kim Andrews, Ramsay Beveridge, Kimberly O Cameron, Chiliu Chen, Matthew Dunn, Dilinie Fernando, Hua Gao, David Hepworth, V Margaret Jackson, Vishal Khot, Jimmy Kong, Rachel E Kosa, Kimberly Lapham, Paula M Loria, Allyn T Londregan, Kim F McClure, Suvi T M Orr, Jigna Patel, Colin Rose, James Saenz, Ingrid A Stock, Gregory Storer, Maria VanVolkenburg, Derek Vrieze, Guoqiang Wang, Jun Xiao, Yingxin Zhang, Samit K Bhattacharya, Kim Andrews, Ramsay Beveridge, Kimberly O Cameron, Chiliu Chen, Matthew Dunn, Dilinie Fernando, Hua Gao, David Hepworth, V Margaret Jackson, Vishal Khot, Jimmy Kong, Rachel E Kosa, Kimberly Lapham, Paula M Loria, Allyn T Londregan, Kim F McClure, Suvi T M Orr, Jigna Patel, Colin Rose, James Saenz, Ingrid A Stock, Gregory Storer, Maria VanVolkenburg, Derek Vrieze, Guoqiang Wang, Jun Xiao, Yingxin Zhang
Abstract
The identification of potent, highly selective orally bioavailable ghrelin receptor inverse agonists from a spiro-azetidino-piperidine series is described. Examples from this series have promising in vivo pharmacokinetics and increase glucose-stimulated insulin secretion in human whole and dispersed islets. A physicochemistry-based strategy to increase lipophilic efficiency for ghrelin receptor potency and retain low clearance and satisfactory permeability while reducing off-target pharmacology led to the discovery of 16h. Compound 16h has a superior balance of ghrelin receptor pharmacology and off-target selectivity. On the basis of its promising pharmacological and safety profile, 16h was advanced to human clinical trials.
Keywords: Ghrelin; PF-5190457; diabetes; ghrelin receptor antagonist; ghrelin receptor inverse agonist.
Figures
Source: PubMed